One of the most frequent deletions in hepatocellular carcinoma (HCC) is that involving the long arm of chromosome 4 (30 to 70% of the cases). These chromosomal deletions are closely related to hepatitis B virus (HBV) infection. A tumor suppressor gene (TSG) located on 4q has been proposed in liver carcinogenesis, but has not been identi®ed as yet. Despite previous LOH studies focused on 4q in HCC, a clear minimal common region of deletion (MCRD) could not be delimited. To further investigate the role of chromosome 4q LOH in the pathogenesis of HCC, 85 microsatellite markers spanning chromosome 4q were systematically analysed in a series of 154 well-characterized primary liver tumors. In 59 tumors (38%), LOHs were observed for at least two adjacent markers. Analysis of 31 tumors demonstrating a partial or interstitial 4q deletion allowed to de®ne three MCRDs of 15, 9 and 8 Mb at the 4q22, 4q34 and 4q35 regions, respectively. Seven putative candidate genes located in 4q22, DAPP1, BMPR1B, PKD2, HERC3, SMARCAD1, CEB1 and ENH were screened for mutations but no somatic alterations were identi®ed. Search for relationships between the speci®c regions of deletion and clinical parameters showed a signi®cant association between loss of the 4q34-35 region with alcohol intake (P=0.005) and with high grade of dierentiation (P=0.02). These results are in contrast with the close association between HBV infection and the whole 4q LOH and reveal heterogeneity of 4q LOH in relation to dierent risk factors. In the light of these new ®ndings, which link dierent 4q LOH regions to dierent etiologic factors, the molecular mechanisms underlying 4q deletions in HCC and the targeted gene(s) remain to be identi®ed.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in Asia and Africa. Recently, its incidence has substantially increased in United Kingdom, France and United States (Deuc et al., 1998; El-Serag and Mason, 1999; Taylor-Robinson et al., 1997) . Etiological factors that have been associated with the development of the disease are well known and include infection with the hepatitis B virus or hepatitis C virus, heavy alcohol intake, prolonged dietary exposure to A¯atoxin B1 and primary hemochromatosis (Tsukuma et al., 1993) . Overall, HCC development is closely associated with cirrhosis and more than 80% of the tumors are found in a cirrhotic background. Nevertheless, the molecular mechanisms of liver carcinogenesis are still poorly elucidated. Although the spectrum of HCC risk factors is very large, common genetic alterations occur in tumors. Among them, the most common are hyperploidy, loss of heterozygosity (LOH), tumor suppressor gene (TSG) inactivation and oncogene activation (Buendia, 2000; Laurent-Puig et al., 2001) . Cytogenetic, allelotyping and comparative genomic hybridization (CGH) analyses have demonstrated frequent deletions on chromosome 1p, 4q, 6q, 8p, 9p, 13q, 16 and 17p in HCC, suggesting existence of TSG on these chromosome arms (Boige et al., 1997; Laurent-Puig et al., 2001; Marchio et al., 1997; Nagai et al., 1997) . TSG like p53, RB1, M6P/IGF2R and most recently Axin1 have been found altered as a consequence of chromosomal losses of 17p, 13q, 6q and 16p, respectively (Buetow et al., 1992; De Souza et al., 1995; Satoh et al., 2000; Zhang et al., 1994) . For the other chromosomal losses, TGS are not yet identi®ed and remain to be found.
Previous cytogenetic and molecular genetic analyses have reported frequent deletion of the long arm of chromosome 4 in 30 to 74% of HCC tumors. We showed that chromosome 4q LOH occurs most frequently in a context of chromosome instability and is recurrently associated with LOH of 1p, 13q, 16p, 16q and Axin1 mutations (Laurent-Puig et al., 2001) . Several allelotyping and CGH series revealed that chromosome 4q LOH is more common in HBV infected tumors, suggesting that TSG on 4q may interact with this virus (Laurent-Puig et al., 2001; Marchio et al., 2000; Wong et al., 2000) . Other associations of 4q LOH with large tumor size, aggressive histological type and high serum alphafetoprotein level have been described in HCC tumors (Bando et al., 1999; Piao et al., 1998; Yeh et al., 1996) , but their independence from the HBV status remains questionable.
Despite previous allelotypes focused on chromosome 4q in HCC, a de®nite minimal common region of deletion (MCRD) still remains to be identi®ed. At least ®ve non-overlapping regions have been reported, being the most frequent regions within 4q21-q25, 4q28 and 4q35 (Bando et al., 1999; Bluteau et al., 1999; Piao et al., 1998; Yeh et al., 1996) . Since a stringent de®nition of the boundaries of the MCRD is the ®rst step necessary to localize and identify the 4q TSG, in this study we systematically analysed 85 microsatellite markers spanning chromosome 4q to assess LOH in a series of 154 well-characterized primary liver tumors.
Results

Deletion mapping of chromosome 4q
The whole series of primary liver tumors including 154 matched tumor and non-tumor DNA pairs was analysed with 85 microsatellite markers distributed on chromosome 4q. Distance between any two genotyped markers varies from 0 to 12.5 cM with an average of 2 cM according to the Genethon genetic map ( Figure  1 ). Microsatellite instability was not observed in more than 2% of the markers and all the tumors were informative for an average of 68% of the tested loci. LOH was determined by quantitative¯uorescent genotyping and all putative deletions de®ned by one marker only were con®rmed with a second microsatellite or SNP genotype in the vicinity. In 59 cases (38%) a chromosome 4q deletion was observed. A deletion was observed at all informative markers in 23 tumors consistent with a complete monosomy of 4q. In the other cases, deletions were partial, including the telomere (17 cases), interstitial (15 cases) or noncontiguous (four cases). Unique interstitial and partial deleted regions were used to de®ne the MCRDs, whereas tumors showing multiple regions of deletion (Figure 1 group D) , or including both the centromeric and the telomeric MCRDs (Figure 1 group A) were excluded from this analysis. The most proximal region, mapping on 4q22 between D4S395 and D4S2986, was clearly de®ned by nine interstitial deletions (Figure 1 , group B). To further re®ne the extent of 4q22 MCRD, we selected and sequenced¯anking SNP markers in critical tumors (CHC019 and CHC241) compared to their matching non-tumor DNA. New 4q22 region boundaries were de®ned by A/C-231 and D4S2986 markers delineating a 15 Mb critical region (Figure 2) .
The telomeric MCRD was more dicult to delineate as CHC121, CHC210 and CHC188 demonstrated nonoverlapping deleted regions (Figure 1 , group C). Genotyping adjacent SNP markers con®rmed interstitial deletions in tumors CHC121 and CHC188. The telomeric MCRD had to be divided in two noncontiguous subregions, de®ned by only one interstitial deletion each. In 4q34 the MCRD is located between rs1564498 and D4S1584 markers de®ning a region of 9 Mb. The interstitial deletion in CHC121 de®ned a MCRD in 4q35 between D4S2943 and D4S426. A precise physical map of this last region is not available, as a lot of discrepancies exist between the dierent sequence databases, but its size can be estimated at approximately 8 Mb.
Mutation detection in candidate genes
In the common deleted region at 4q22 more than 30 genes have been mapped on the UCSC genome draft map ( Figure 2 ). Among them, we successively identi®ed seven candidate genes on the basis of their known or putative role in the control of the cell growth or in dierentiation.
(1) Bone morphogenetic protein receptor 1B (BMPR1B or ALK6) is a transmembrane serine/threonine kinase member of the TGF-beta receptor's superfamily that plays a pivotal role in bone formation during embryogenesis and fracture repair. Furthermore, germline mutations of BMPR1A located on chromosome 10q have been recently identi®ed in juvenile polyposis families (Howe et al., 2001) . (2) The dual adaptor of phosphotyrosine and 3-phosphoinositides (DAPP1) contains a src homology 2 (SH2) and a pleckstrin homology (PH) domains (Dowler et al., 1999) . This protein is likely to play an important role in triggering signal transduction pathways that lie downstream from receptor tyrosine kinases and PI3-kinase. Initially located within our 4q22 critical region, genotyping SNP in DAPP1 demonstrated a retention of heterozygosity in tumor CHC241, pushing the gene outside the MCRD (Figure 2 ). (3) Inactive mutations of PKD2 are the cause of autosomal dominant polycystic kidney disease type II (ADPKD type II), a common autosomal dominant genetic disease characterized by progressive formation and enlargement of cysts in both kidneys and liver (Mochizuki et al., 1996) . (4) The cyclin E binding protein 1 (CEB1/LOC51191) belongs to the HECT family and also contains RCC1-like repeats (Mitsui et al., 1999) . (5) HERC3 is a member of the HERC (domain homologous to E6 associated protein carboxy-terminus and RCC1 domain protein) family. It may function both as guanine nucleotide exchange factor and E3 ubiquitin ligase and may play a role in vesicular trac and ubiquitindependent processes (Cruz et al., 2001) . (6) SMAR-CAD1 is a DEAD/H box-containing molecule that belongs to the snf2 helicase superfamily including proteins essential to genome replication, repair, and expression (Adra et al., 2000) . (7) ENH is a protein with a LIM domain that belongs to the Enigma family proteins involved in cytoskeleton organization, cell lineage speci®cation, organ development, and oncogenesis (Kuroda et al., 1996) . Screening 28 HCC tumor and cell line DNAs on the entire coding region of BMPR1B, DAPP1, PKD2, SMARCAD1 and ENH for mutations revealed rare polymorphisms but no somatic alterations. To screen for alterations in CEB1 and HERC3 genes, as they contain more than 20 exons, RT/PCR was performed, followed by direct sequencing on 10 RNAs extracted from HCC cell lines. No somatic mutations, abnormal transcripts or clear downregulation of the transcription level were shown using a semi-quantitative analysis of the RT ± PCR products.
Correlations between clinical characteristics and specific 4q MRCD
The frequency of 4q LOH, whatever the region lost, was similar in the three major histopathological subgroups: (a) HCC, 39% (53 of 133 tumors), (b) FLC, 29% (two of seven tumors); and (c) mixed hepato-cholangiocarcinoma 56% (®ve of nine tumors). In contrast, all the ®ve benign liver tumors retained both chromosomes 4q. Relationships between tumor histo-clinical parameters and the extent of 4q LOH regions were further examined in the group of 133 classical HCC. As described in Laurent-Puig et al., 2001, a close relation exists between 4q LOH, whatever the region, and HBV infection (P50.0001), and absence of alcohol intake (P50.001). In contrast to these established relationships, the speci®c deletion of the 4q34-35 region is associated with a high grade of dierentiation of the tumors (Edmondson grade I or II) (P=0.02) and a heavy alcohol intake (P=0.005) (Figure 3) . Furthermore, the speci®c 4q22 deletions are related to the small size of the tumors (P=0.008). To test the relative in¯uence of the clinical parameters on the speci®c subregion of the deletions, we integrated the three variables (alcohol intake, dierentiation and diameter) in a maximum-likelihood logistic regression model. With this analysis, we demonstrated that heavy alcohol intake or high grade of dierentiation of the tumors are independently associated with the loss of 4q34-35 region.
Discussion
Allelotype studies and CGH assays have identi®ed high frequency of deletions on 4q in HCC, consistent with the presence of one or more TGSs on this chromosomal arm (Bando et al., 1999; Boige et al., 1997; Laurent-Puig et al., 2001; Nagai et al., 1997; Piao et al., 1998; Yeh et al., 1996) . These studies, however, suer from the lack of extensive and systematic deletion mapping analysis in delineating the exact location of MRCDs. To further de®ne the critical regions of chromosome 4q deletions, we performed a systematic high-density allelotyping. We identi®ed 59 tumors (38%) with a LOH of chromosome 4q corresponding to our criteria of selection, i.e. (1) a high percentage of allelic height reduction on 4q when compared to the rest of the autosome with a value always inferior to 50% and (2) at least two adjacent markers deleted to de®ne a region of LOH in each tumor. The proportion of HCC demonstrating chromosome 4q loss reported here is consistent with that reported in a series of tumors presenting low rate of HBV infection (30%) and previously allelotyped and studied by CGH (Bando et al., 1999; Boige et al., 1997; Laurent-Puig et al., 2001; Nagai et al., 1997; Piao et al., 1998; Yeh et al., 1996) .
Tumors with complex LOH region have been discarded for MCRD analysis. Therefore, the pattern of allelic losses in the present study identi®ed three discrete regions of minimal deletions. Our de®nition of the proximal 4q22 MCRD includes the two loci D4S1534 and D4S2929 previously identi®ed by Bando et al., 1999 as hot spots of deletion. Even though these two markers have been tested in the present allelotyping analysis, we have not found the same hot spot of deletions in our series of tumors. To explain this discrepancy, dierences in the geographical origin of the patients and/or in the allelotyping techniques could be evoked. In particular, we eliminated all the putative interstitial deletions at a unique locus that could not be con®rmed by a second polymorphic deleted marker to avoid genotyping artifacts. For the distal MCRDs in 4q35, the region de®ned here is in agreement with that described by Bando et al., 1999. We chose to focus our candidate genes screening strategy on the 4q22 MCRD that was non-ambiguously de®ned and because tumors exhibiting a speci®c 4q22 deletion did not dier in their risk factors from those that delete the 4q, whatever the subregion. The 4q22 MCRD contains at least 30 known genes and we screened about a quarter of them for mutations. These screened genes have been selected on their putative function in cell growth and/or dierentiation. Since no alterations were found, we can exclude frequent and recurrent nucleotide mutations of these genes in hepatocarcinogenesis. Finally, more than 50 known genes, located in dierent MCRDs, remain to be tested in HCC tumors even if their possible involvement in hepatocarcinogenesis could not be inferred by their amino acid analysis.
One of the most intriguing results of this study was the identi®cation of the unexpected relationship between alcohol intake and 4q34-35 deletions. The speci®c deletion of the 4q34-35 region de®nes a particular group of tumors, all of which are well dierentiated and have been exposed to alcohol intake. This result is in complete contrast to the established relationship between 4q LOH, whatever the subregion, and HBV infection previously described (Bluteau et al., 1999; Laurent-Puig et al., 2001; Marchio et al., 2000; Wong et al., 2000) . To explain this observation, a de®nite mechanism of alcohol intake leading to generate deletions of the 4q34-35 region might be proposed. Furthermore, since chromosome 4q deletions are rare events in tumors secondary to alcohol abuse, the presence of a TGS located in 4q34-35 is questionable.
In this work we show heterogeneity in HCC tumors in relation to the speci®c 4q subregion deleted. This is Oncogene Chromosome 4q deletions in hepatocellular carcinoma O Bluteau et al an extremely important ®nding in the search for TGS on chromosome 4q, since the delimitation of the MCRDs is crucial. However, in the present series none of the tumors exhibiting an interstitial deletion of the proximal 4q22 had been associated to alcohol abuse. Subsequently, our delineation of the 4q22 MCRD seems to be independent from the putative role of alcohol intake as a risk factor. In conclusion, the LOH data in this study support previous reports that at least two regions are recurrently deleted on chromosome 4q in HCC. TGS(s) located on 4q remain to be identi®ed, but great heterogeneity in the risk factors associated to HCC and underlying dierent deletions has to be taken into consideration in the cloning approach.
Materials and methods
Patients and samples
From 1992 to 1998, primary liver carcinoma and matched non-tumor liver tissues were obtained from 154 patients from four French surgical departments. To the previously reported 133 classical HCC cases (Laurent-Puig et al., 2001), we added seven ®brolamellar carcinomas (FLC), nine tumors presenting mixed cholangio and hepato dierentiation and ®ve benign tumors (two adenomas, three focal nodular hyperplasias). The majority of the patients were born in France (115 cases) while the others have dierent geographical origins (Mediterranean area 15 cases, sub Saharan Africa 12 cases, the Antilles ®ve cases and Asia seven cases). Determination of the dierent risk factors was performed using the methods described in Laurent-Puig et al., 2001 , and alcohol abuse was recorded as a risk factor when the average reported daily alcohol intake was over 80 g during more than 10 years. The histological grade of tumor dierentiation was assigned according to the Edmondson and Steiner grading system. After grading using the Edmondson classi®cation, tumors were classi®ed in two groups (i.e. grade I + II and grade III + IV).
The HCC cell lines SNU-182, SNU-387, SNU-398, SNU-423, SNU-449, SNU-475 and Hep 3B were purchased from American Type Culture Collection (Manassas, VA, USA) and cases PLC/PRF, Malhavu and HUH7 were kindly provided by Mehmet Ozturk (Bilkent University, Ankara, Turkey).
Tumor tissue samples were dissected and non-tumor tissues (450 mg) were taken as far from the tumor as possible. Tissues were stored at 7808C until DNA extraction was performed using the Qiaquick extraction kit (Qiagen, Courtaboeuf, France). DNAs were quanti®ed by¯uorometry (Fluoroskan Thermo LabSystem, Cergy-pontoise, France).
LOH analysis
All the 154 tumor DNA and matching non-tumor DNA were genotyped using 85 microsatellite markers selected from the GeÂ neÂ thon database. The markers used in this study are listed with their localization on chromosome 4q in Figure 1 , Figure 3 Relationships between clinical parameters and 4q deletions strati®ed in speci®c MCRD. For each speci®c deleted region percentage of the patients presenting the clinical parameter indicated in x-axis is scored. Statistically signi®cant relationships are indicated with their P value obtained using a Fischer's exact test To re®ne the boundaries of MCRD regions, we PCR ampli®ed fragments of 0.8 kb randomly or centered on SNP described in the Single nucleotide polymorphism consortium (http://www.ncbi.nlm.nih.gov/SNP). LOH status assignment was determined by measurement of the relative height of the allelic peaks at the polymorphic position in the sequence of the tumor PCR fragment compared to the matching non-tumor one.
% of cases
Physical map
All physical map informations used in this work were available in the Human Genome Project Working Draft at UCSC (http://genome.ucsc.edu/, (Lander et al., 2001) ). In selective situations, to control the order of markers or to ®ll a gap, for example, MapViewer and Blast on GenBank databases at the NCBI (http://www.ncbi.nlm.nih.gov) were used.
Search for gene alterations
A panel of 21 tumors deleted on chromosome 4q22 and seven cell lines was tested for genetic alterations in candidate genes. Tumor DNA samples were assessed for mutations in seven identi®ed genes mainly using DHPLC with the Helix system according to the manufacturer's recommendations (Varian, Les Ulis, France). For all samples demonstrating a chromosome 4q22 LOH with an allelic height reduction in the tumor of more than 80%, DHPLC analyses were performed both using tumor DNA pure and mixed with 50% of the autologous non-tumor DNA sample to allow heteroduplex formation. Aberrant DHPLC fragments were reampli®ed and sequenced directly on an ABI 377 automatic sequencer (Applied Biosystems). Whenever an alteration was detected in tumor DNA, DNA from autologous normal tissue was also analysed. In case of frequent polymorphisms identi®ed in the GenBank database or experimentally (i.e. 15% of the exons), screening for mutations was performed by direct sequencing of the PCR products analysed with the Factura and Autoassembler softwares (Applied Biosystems).
In case of the HERC3, CEB1 and SMARCAD1, because of the large number of exons (HERC3 and CEB1) or because 35% of the genomic sequence were not available (SMAR-CAD1), reverse-transcriptase PCR was performed to search genetic alterations in the 10 cell lines. In each case, the entire known coding sequence was ampli®ed in three (SMARCAD1 and HERC3) or ®ve (CEB1) overlapping fragments and subsequently ampli®ed fragments were directly sequenced. PCR primers and sequencing primers used in this project are available upon request.
Statistical analysis
To test for associations between chromosome 4q LOH and clinical parameters, comparisons were made using w 2 or Fisher exact test when appropriate. Three categories of 4q deletions were determined to assess the possible biological eect of a 4q deletion in patients: centromeric (4q22), telomeric (4q34-35) and deletions that include both regions. Logistic regression model was performed using the Stata software (Stata Corporation, College Station, TX, USA).
